1. Home
  2. VIGL vs EURK Comparison

VIGL vs EURK Comparison

Compare VIGL & EURK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIGL
  • EURK
  • Stock Information
  • Founded
  • VIGL 2020
  • EURK 2023
  • Country
  • VIGL United States
  • EURK Hong Kong
  • Employees
  • VIGL N/A
  • EURK N/A
  • Industry
  • VIGL Biotechnology: Pharmaceutical Preparations
  • EURK
  • Sector
  • VIGL Health Care
  • EURK
  • Exchange
  • VIGL Nasdaq
  • EURK NYSE
  • Market Cap
  • VIGL 89.3M
  • EURK 80.0M
  • IPO Year
  • VIGL 2022
  • EURK 2024
  • Fundamental
  • Price
  • VIGL $2.64
  • EURK $10.20
  • Analyst Decision
  • VIGL Strong Buy
  • EURK
  • Analyst Count
  • VIGL 5
  • EURK 0
  • Target Price
  • VIGL $21.00
  • EURK N/A
  • AVG Volume (30 Days)
  • VIGL 2.6M
  • EURK 1.1K
  • Earning Date
  • VIGL 03-25-2025
  • EURK 01-01-0001
  • Dividend Yield
  • VIGL N/A
  • EURK N/A
  • EPS Growth
  • VIGL N/A
  • EURK N/A
  • EPS
  • VIGL N/A
  • EURK 0.18
  • Revenue
  • VIGL N/A
  • EURK N/A
  • Revenue This Year
  • VIGL N/A
  • EURK N/A
  • Revenue Next Year
  • VIGL N/A
  • EURK N/A
  • P/E Ratio
  • VIGL N/A
  • EURK $55.36
  • Revenue Growth
  • VIGL N/A
  • EURK N/A
  • 52 Week Low
  • VIGL $1.49
  • EURK $10.03
  • 52 Week High
  • VIGL $6.06
  • EURK $10.20
  • Technical
  • Relative Strength Index (RSI)
  • VIGL 71.47
  • EURK N/A
  • Support Level
  • VIGL $2.22
  • EURK N/A
  • Resistance Level
  • VIGL $2.53
  • EURK N/A
  • Average True Range (ATR)
  • VIGL 0.29
  • EURK 0.00
  • MACD
  • VIGL 0.08
  • EURK 0.00
  • Stochastic Oscillator
  • VIGL 80.47
  • EURK 0.00

About VIGL Vigil Neuroscience Inc.

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

About EURK EUREKA ACQUISITION CORP

Eureka Acquisition Corp is a newly incorporated blank check company.

Share on Social Networks: